Foghorn Therapeutics financials
$3.520.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.1M | $3.3M | $9.2M | $8.2M | $7.6M | $6.0M | $2.9M | $7.8M | $6.9M | $5.0M | $5.8M | $17.5M |
| Gross profit | $16.1M | $3.3M | $9.2M | $8.2M | $7.6M | $6.0M | $2.9M | $7.8M | $6.9M | $5.0M | $5.8M | $17.5M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$8.8M | -$21.6M | -$23.9M | -$18.5M | -$21.1M | -$22.9M | -$24.0M | -$23.9M | -$26.6M | -$28.2M | -$25.5M | -$17.1M |
| Net income | -$7.2M | -$19.9M | -$21.7M | -$15.8M | -$17.9M | -$18.8M | -$19.5M | -$19.1M | -$23.0M | -$25.0M | -$24.1M | -$14.3M |
| Net margin | −44.7% | −608.4% | −234.3% | −194.4% | −237.3% | −316.4% | −682.9% | −244.9% | −333.6% | −495.4% | −417.9% | −82.1% |
| Diluted EPS | $-0.10 | $-0.29 | $-0.34 | $-0.25 | $-0.28 | $-0.30 | $-0.31 | $-0.31 | $-0.45 | $-0.59 | $-0.57 | $-0.34 |
| EBITDA | -$8.6M | -$21.3M | -$17.2M | -$17.6M | -$20.2M | -$22.1M | -$23.2M | -$23.1M | -$23.4M | -$27.4M | -$24.6M | -$16.2M |
| Operating cash flow | -$17.8M | -$25.3M | -$22.3M | -$18.9M | -$21.0M | -$24.0M | -$24.5M | -$21.0M | -$25.5M | -$29.3M | -$27.5M | -$27.2M |
| Free cash flow | -$17.9M | -$25.3M | -$22.3M | -$18.9M | -$21.0M | -$24.0M | -$25.0M | -$21.3M | -$25.6M | -$29.4M | -$27.6M | -$27.3M |
| Diluted shares | 70.6M | 69.5M | 63.1M | 63.0M | 63.0M | 62.8M | 63.0M | 62.6M | 51.6M | 42.4M | 42.2M | 42.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $68.1M | $87.7M | $80.9M | $89.3M | $72.6M | $61.0M |
| Short-term investments | $99.5M | $96.0M | $78.0M | $90.9M | $126.1M | $159.6M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $203.4M | $222.2M | $198.1M | $205.0M | $226.2M | $258.7M |
| Total liabilities | $284.4M | $298.6M | $306.6M | $294.6M | $302.9M | $320.3M |
| Shareholders' equity | -$81.0M | -$76.4M | -$108.5M | -$89.7M | -$76.7M | -$61.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology